Oncotarget · 2016 · 18 citations · 30 references
PharmacyOncologyPharmaceuticsDrug DeliveryMolecular OncologyTargeted Drug DeliveryCancer Drug DeliveryCancer NanomedicineLung CancerTargeted Cancer TherapyDendrimer Drug DeliveryDendrimer-based DeliveryGene Delivery NanocarriersGene Delivery NanoparticlesGene-targeted TherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer Treatment
// Quan Huang 1, 2, * , Lei Li 1, 2, * , Lin Li 1, * , Hui Chen 2 , Yongyan Dang 2 , Jishen Zhang 1 , Naimin Shao 2 , Hong Chang 2 , Zhengjie Zhou 2 , Chongyi Liu 2 , Bingwei He 2 , Haifeng Wei 1 , Jianru Xiao 1 1 Department of Orthopedic Oncology, Changzheng Hospital, The Second Military Medical University, Shanghai, PR China 2 Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai, PR China * These authors have contributed equally to this work Correspondence to: Jianru Xiao, email: jianru_xiao12345@163.com Haifeng Wei, email: haifeng_wei123@163.com Keywords: dendrimer, MDM2, gene delivery, siRNA, non-small cell lung cancer Received: March 22, 2016 Accepted: May 13, 2016 Published: June 01, 2016 ABSTRACT Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the five-year survival rate is lower in advanced NSCLC patients. Chemotherapy is a widely used strategy in NSCLC treatment, but is usually limited by poor therapeutic efficacy and adverse effects. Therefore, a new therapeutic regimen is needed for NSCLC treatment. Gene therapy is a new strategy in the treatment of NSCLC. However, the lack of efficient and low toxic vectors remains the major obstacle. Here, we developed a biocompatible dendrimer as a non-viral vector for the delivery of mouse double minute2 (MDM2) siRNA in vitro and in vivo to treat NSCLC. The triazine-modified dendrimer efficiently stimulates the down-regulation of MDM2 gene in NSCLC PC9 cells, which induces significant cell apoptosis through the activation of apoptosis markers such as caspase-8 and poly(ADP-ribose) polymerase (PARP) cleavage. Furthermore, the dendrimer/MDM2 siRNA polyplexes showed excellent activity in the inhibition of tumor growth in a PC9 xenograft tumor model. These results suggested that inhibition the expression of MDM2 might be a potential target in NSCLC treatment.
30
Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2013 · 11.9K citations · Full text
The Global Burden of Cancer 2013
Christina Fitzmaurice, Daniel Dicker, Amanda Pain et al. · JAMA Oncology · 2015 · 2.8K citations · Full text
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Reiko Honda, Hirofumi Tanaka, Hideyo Yasuda · FEBS Letters · 1997 · 1.9K citations
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Stephen N. Jones, Amy E. Roe, Lawrence A. Donehower et al. · Nature · 1995 · 1.3K citations